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CCL2 nitration is a negative 
regulator of chemokine-mediated 
inflammation
Catriona E. Barker1, Sarah Thompson1, Graeme O’Boyle2, Hugues Lortat-Jacob3, 
Neil S. Sheerin1, Simi Ali1 & John A. Kirby1
Chemokines promote leukocyte recruitment during inflammation. The oxidative burst is an important 
effector mechanism, this leads to the generation of reactive nitrogen species (RNS), including 
peroxynitrite (ONOO). The current study was performed to determine the potential for nitration to alter 
the chemical and biological properties of the prototypical CC chemokine, CCL2. Immunofluorescence 
was performed to assess the presence of RNS in kidney biopsies. Co-localisation was observed between 
RNS-modified tyrosine residues and the chemokine CCL2 in diseased kidneys. Nitration reduced the 
potential of CCL2 to stimulate monocyte migration in diffusion gradient chemotaxis assays (p < 0.05). 
This was consistent with a trend towards reduced affinity of the nitrated chemokine for its cognate 
receptor CCR2b. The nitrated chemokine was unable to induce transendothelial monocyte migration 
in vitro and failed to promote leukocyte recruitment when added to murine air pouches (p < 0.05). 
This could potentially be attributed to reduced glycosaminoglycan binding ability, as surface plasmon 
resonance spectroscopy showed that nitration reduced heparan sulphate binding by CCL2. Importantly, 
intravenous administration of nitrated CCL2 also inhibited the normal recruitment of leukocytes to 
murine air pouches filled with unmodified CCL2. Together these data suggest that nitration of CCL2 
during inflammation provides a mechanism to limit and resolve acute inflammation.
The mechanisms by which ongoing inflammation is resolved are unclear. Limiting the production of 
pro-inflammatory factors, including chemokines, is one potential mechanism. Others include the generation of 
steroids, nitric oxide, adenosine, interleukin-10 and regulatory T cells1,2. A recently-described further candidate 
is endogenous chemical modification of existing cytokines leading to alteration of their biological properties.
The infiltration of immune cells able to perform oxidative burst is a major and recurring cause of tissue injury 
during inflammation. Macrophages and neutrophils produce nitric oxide and the superoxide anion by inducible 
NO synthase and NADPH oxidase respectively, which react to form peroxynitrite. Reactive oxygen species, for 
example H2O2, are well known to be associated with inflammation3. However, fewer studies have explored the 
contribution of RNS such as peroxynitrite4. Peroxynitrite is a major oxidant in pathological conditions associ-
ated with oxidative stress including diabetes5, organ transplant6 and cancer7. Peroxynitrite can spontaneously 
nitrate aromatic amino acids including tyrosine and tryptophan, and it also oxidises the thiol group of methio-
nine and cysteine to sulfoxide. The short half-life of peroxynitrite prevents its detection in vivo, but the biomarker 
3-nitrotyrosine is indicative of its presence. It is known that nitration can modify protein functions8. For example, 
peroxynitrite can alter the function of transcription factors such as NFκ B resulting in, altered cell adhesion mole-
cule expression9. Oxidative stress can alter other transcription factors such as HIF-1α and p53 further developing 
the stress response, and can also increase mitochondrial permeability allowing signalling molecules to transition 
both to and from the nucleus10.
Chemokines, are small (8–14 kDa) chemoattractant cytokines secreted by many cell types. Chemokines can 
be regulated at the transcriptional and translational levels by oxidative stress. Some preformed chemokines are 
stored in endothelial cells, in secretory granules including Weibel-Palade bodies allowing a rapid response to 
insult11. Once produced, the functions of chemokines are also closely regulated by post-translational modifica-
tion12, receptor expression and GAG binding13. Chemokines typically bind and signal through G-protein coupled 
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receptors but decoy, or atypical, receptors can also bind chemokines, generally with anti-inflammatory effects14. 
In order to form the chemokine gradients needed for in vivo function, chemokines bind to GAGs such as heparan 
sulphate15,16. Endothelial expression of these cell surface GAGs increases during the stresses induced by trans-
plantation, resulting in increased endothelial potential to bind and present chemokines17.
Chemokines are well known targets for post-translational modification, with enzymatic processing altering 
their biology6,18,19. For example, matrix metalloproteinases are released by stressed cells and can cleave chemok-
ines20, whilst peptidylarginine deiminases can inactivate certain chemokines by citrullination21. Several chemok-
ines have also been found to be targets of peroxynitrite modification, including CCL28,22,23 and CCL58. Generally 
it is thought that modification of proinflammatory cytokines by peroxynitrite abrogates function, but this is 
dependent on numerous factors, including cell type, anti-oxidant levels (scavenger glutathione) etc. A recent 
study showed that peroxynitrite-treated CCL2 lost its ability to recruit CD8+ T cells, but the recruitment of 
myeloid-derived suppressor cells was unaltered23. No mechanisms of action have been defined. Molon et al.23 
reported that nitrated CCL2 cannot be detected by commercially available antibodies as the modification causes 
epitope loss. This has important implications for studies using antibody based techniques to study chemokine 
levels in inflammatory environments.
The current study was designed to explore the potential of nitrated chemokines to regulate inflammation. 
CCL2 was chosen as a prototypical chemokine as it is produced by various cell types in response to diverse 
stimuli including oxidative stress. Initial experiments were performed to validate the potential expression of 
nitrated CCL2 in inflamed human renal tissue biopsies. We then used several models to demonstrate that nitra-
tion reduced the potential of CCL2 to induce inflammation. Importantly, we also showed that nitrated CCL2 was 
able to inhibit the activity of unmodified CCL2 in vivo. A final experiment demonstrated that nitration removed 
the potential of CCL2 to bind heparan sulphate suggesting a mechanism for the anti-inflammatory activity of this 
inflammation-modified chemokine.
Results
Protein nitration in ischaemia–reperfusion injury. In order to examine the effects of oxidative stress 
in vivo, we used biopsy sections taken from patients who had been diagnosed with acute tubular necrosis (ATN) 
caused by ischaemia reperfusion injury (IRI) sustained during kidney transplantation. This was compared to 
staining in kidney sections from the unaffected pole of tumour nephrectomies. 3-nitrotyrosine appeared to be 
present constitutively, particularly in the tubules, in both normal and ATN kidneys (Fig. 1); a staining pattern 
which has been previously documented24. However, it is clear that expression of CCL2 within the tubules increases 
greatly after IRI in comparison to the levels observed in normal kidneys. The staining patterns for CCL2 and 
3-nitrotyrosine co-localize largely in the tubules of the injured kidney (confirmed by the yellow pixels indicating 
co-localization in the cytofluorograms) suggesting the presence of NO2-CCL2 at this site. Presence of increased 
amount of nitrated chemokine was also detected in rejecting cardiac transplant biopsy (Supplementary Figure 1).
Figure 1. Protein nitration in ischaemia–reperfusion injury. Kidney sections from patients diagnosed 
with ATN as a result of ischaemia-reperfusion injury sustained during kidney transplant were stained by 
immunofluorescence for 3-nitrotyrosine and CCL2. 3-nitrotyrosine staining was developed with a FITC 
conjugated secondary (green), CCL2 was developed with a Dylight-550 conjugated secondary (red), and nuclei 
were counterstained with DAPI (blue). Four patient samples, and six normal kidney samples were tested and 
representative images are shown. Original magnification x20, taken on Nikon A1 Confocal microscope, with 
co-localization analysis performed using Volocity software. Bars, 50 μ m. Insert - no primary antibody control.
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Chemokines including CCL2 are produced during IRI. Furthermore, RNS modulate inflammation by 
post-translational modification of chemokines. In order to examine the role of nitrated CCL2 in inflammation 
we exposed CCL2 to peroxynitrite for 10 minutes and the presence of modification was determined by tryp-
tic digest and tandem mass spectrometry coupled to liquid chromatography (LC-MS/MS). Both tyrosines 
(Y13 and Y28) and tryptophan (W59) were reproducibly modified by nitration. Methionine oxidation was also 
found but is a common artefact during mass spectrometry which cannot be attributed solely to peroxynitrite 
(Supplementary Figure 2).
Effect of nitration on biological activity of CCL2. In order to examine the biological properties of 
NO2-CCL2, chemotaxis assays were carried out. Figure 2 shows CCL2 nitration decreases its ability to recruit 
monocytes in a dose dependent manner using diffusion gradient chemotaxis assays. Furthermore, to determine 
whether nitration affected the interaction between CCL2 and its cognate receptor CCR2b, the effect of CCL2 
nitration on chemotaxis of HEK-CCR2b transfectants was assessed (signalling via a single receptor). Migration 
of HEK-CCR2b transfectants was significantly reduced at 10 nM concentration of NO2-CCL2 compared with 
WT-CCL2, indicating that nitration alters the biological activity of CCL2. As no significant difference was 
observed at 50 nM, this suggests that the reduction in migration in response to 10 nM NO2-CCL2 is due to nitra-
tion reducing the chemokine activity; an affect that can be countered by saturating the system with a higher 
concentration of nitrated chemokine.
Figure 2. Diffusion gradient chemotaxis comparing the ability of WT-CCL2 and NO2-CCL2 to elicit 
migration. Migrated monocytes and HEK-CCR2b adhered to the underside of the filter and 5 high power fields 
(hpf; 400× ) counted per filter. Data shows nitration decreases the chemotactic ability of CCL2 for monocyte 
migration and at least some of this is through CCR2b. White bars - CCL2, black bars - NO2-CCL2. No 
chemokine control displayed by dotted lines. Representative data of three independent experiments, performed 
in triplicate. Data is presented as mean ± SEM, statistical analysis by Student’s t-test. Images shown are examples 
of a high power field (HPF) taken at 20× magnification from the 10 nm filters.
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Effect of nitration on binding of CCL2 to its receptor CCR2. To determine if the decrease in recruit-
ment of HEK-CCR2b in response to NO2-CCL2 compared to CCL2 was due to decrease in CCR2b binding, a 
series of radioligand binding assays were carried out. Representative homologous cold-ligand competition curves 
for 125I-CCL2 are shown in Fig. 3. The IC50 value for WT-CCL2 and NO2-CCL2 was found to be 3.71 ± 1.138 and 
21.2 ± 8.2 nM respectively (mean ± S.D., n = 3). Although this difference did not reach statistical significance, the 
trend suggests that nitration reduced the affinity of CCL2 for CCR2 around 6-fold.
Transendothelial chemotaxis. A further series of experiments was performed to compare the potential 
of WT and NO2-CCL2 to stimulate the migration of monocytes across endothelium. In these assays, endothelial 
cells were cultured to confluency on the upper surface of a porous filter. Both the WT or NO2-CCL2 was then 
added to the basal compartment and mononuclear cells were introduced above the apical surface of the model 
endothelium. In contrast to the results for trans-filter migration, it was found that the NO2-CCL2 stimulated 
no increase in transendothelial cell migration when used at 1, 10 and 50 nM concentrations (p < 0.05; Fig. 4). 
However, WT-CCL2 stimulated significantly increased leukocyte migration at each of the tested concentrations 
(all p < 0.001).
Effect of nitration on Glycosaminoglycan (GAG) interaction. To assess the impact of nitration on 
chemokine GAG binding WT-CCL2 and NO2-CCL2 were assessed in solid phase heparin binding assays. The 
NO2-CCL2 did not significantly bind to immobilised heparin. This result was confirmed by Surface Plasmon 
Resonance (SPR) measurements in which reducing end biotinylated heparan sulphate (or heparin) was cap-
tured on top of a streptavidin sensorchip. This system mimicked cell membrane-anchored proteoglycans and 
SPR spectroscopy was used to measure changes in the refractive index caused by the interaction that occurred 
when a range of concentrations of WT or NO2-CCL2 were flowed across the immobilized GAG sensorchips. 
The resulting sensorgrams (Fig. 5) demonstrated that WT-CCL2 can interact with heparan sulphate, whereas no 
specific binding could be detected for NO2-CCL2 at concentrations up to 500 nM. Similar results were observed 
for interactions with heparin.
Investigation of the role of nitration in chemokine-mediated inflammation. The stable air 
pouches formed on the back of mice develop a lining which resembles the synovial membrane25. Introduction 
of 10 μ g of WT-CCL2 to air pouches induced significant recruitment of leukocytes within 18 h. Recruitment 
in response to CCL2 was significantly higher than to either PBS or NO2-CCL2, with migration in response to 
NO2-CCL2 and PBS not significantly different (Fig. 6). Interestingly, the mean recruitment of cells in response to 
NO2-CCL2 is lower than that of PBS group, although this did not reach significance.
A further series of experiments was performed to assess the effect of intravenous administration of NO2-CCL2 
on the intra-air pouch inflammatory response. The negative control group, with intravenous PBS and intrapouch 
PBS, showed levels of infiltrating leukocytes that were similar to those in earlier experiments (Fig. 7). Interestingly, 
intravenous administration of NO2-CCL2 to animals with WT-CCL2 in their air pouches resulted in a significant 
decrease in the number of cells recruited to the pouch compared with groups that received WT-CCL2 intrave-
nously and WT-CCL2 in pouch (P < 0.001). These data suggest that systemic administration of NO2-CCL2 is able 
to inhibit localized, CCL2-mediated inflammation within the air pouch.
Discussion
During inflammation leukocytes migrate to the damaged site to neutralise the induction of chemotactic stimuli. 
It is generally believed that the removal of stimulus will stop any further pro-inflammatory mediator synthesis 
(e.g. chemokine, adhesion molecules) allowing resolution of inflammation. However, several anti-inflammatory 
agents including nitric oxide, IL-1026 and endogenous negative regulators of leukocyte recruitment such as 
Figure 3. Radioligand binding assays. Results from a representative heterologous cold competition-
binding assay conducted using HEK-293 cells transfected to stably express CCR2b, 125I-labeled CCL2 as 
the radiolabelled ligand, and a variable concentration of either unlabelled CCL2 (▪ ) or NO2-CCL2 (▴ ) as 
competitors. Results shows nitration decreases receptor binding (IC50 CCL2 = 3 nM, NO2-CCL2 = 36 nM).
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pentraxin-3 and endothelium-derived developmental endothelial locus-1 (Del-1) have been identified27. These 
observations have challenged the concept that the resolution of inflammation is simply a passive process.
Previous studies have shown that modification of proinflammatory cytokines and chemokines by peroxyni-
trite can alter their function8,22,23. Peroxynitrite can selectively oxidise and nitrate several residues, including the 
oxidation of histidine and the nitration of tyrosine and tryptophan. Nitration of tyrosine results in the formation 
of 3-nitrotyrosine. This gives the modified residue a 45 Da mass increase but the overall charge remains unaltered. 
3-nitrotyrosine is a marker of nitro-oxidative stress and the presence of peroxynitrite is seen in many pathological 
conditions, including diabetes and transplantation4. Antibodies have been raised against 3-nitrotyrosine and are 
used to identify nitrated proteins and the presence of peroxynitrite or related species23. Our data demonstrates 
the use of such antibodies to show co-localisation of 3-nitrotyrosine and CCL2 in kidney samples from patients 
with ATN. Chemokine nitration has previously been identified in vivo for CCL2 by immunohistochemistry and 
ELISA23.
NO2-CCL2 showed reduced directional leukocyte migration in a chemokine concentration gradient produced 
by free solute diffusion (trans-filter). This reduced potential was seen both with T cells (data not shown) and 
monocytes; however cell recruitment in response to NO2-CCL2 remained significantly higher than the back-
ground. Furthermore, in this study it has been demonstrated that NO2-CCL2 can interact with specific chemok-
ine receptors. Although nitration caused a reduction of affinity by around 6-fold, previous studies have shown 
that this level of reduction in affinity is not sufficient to abrogate the function of chemokine28.
It is unlikely that a stable solute concentration gradient could occur in vivo for periods of time required for 
tissue inflammation. We further examined the ability of nitrated chemokine to support transendothelial migra-
tion, a more physiologically relevant technique requiring apical presentation of chemokine was carried out. It was 
found that unlike WT-CCL2, the NO2-CCL2 was not capable of inducing transendothelial leukocyte migration 
Figure 4. Chemotaxis comparing the ability of WT-CCL2 and NO2-CCL2 to elicit migration of monocytes 
across an EAhy.926 monolayer. Monocytes adhered to the underside of the filter and 5 hpf were counted per 
filter. Data shows nitration abrogates transendothelial migration in response to CCL2. White bars - CCL2, black 
bars - NO2-CCL2. No chemokine control displayed by dotted lines. Methanol-fixed filters ( A) 10nM NO2-
CCL2, B) 10nM wild type CCL2) stained with heamotoxylin, monocytes stain more intensely than EAhy.926 
s resulting in monocytes appearing as dark spots on a background of EAhy.926 s stained lighter purple. Cells 
which were sharply in focus on the lower surface of the filter membrane, but not on the upper surface were 
counted as migrant. Representative data of three independent experiments, performed in triplicate. Statistical 
analysis by Student’s t-test.
www.nature.com/scientificreports/
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in vitro. A similar failure of cell migration has been reported previously for leukocyte transmigration assays per-
formed using non-GAG binding chemokines15,29,30.
The residues nitrated in CCL2 were identified but exactly which modified residues are responsible for modu-
lation in function is not known. Tyr13 is one of the residues modified and has previously been shown to be crucial 
for CCL2 function31–33. It is involved in receptor binding and signalling and so modification of this amino acid 
could explain the decrease in receptor affinity and diffusion gradient chemotaxis. Our group and others have 
shown that the interaction between chemokines and GAGs is of crucial importance for inflammatory migration 
of leukocytes through monolayers of endothelial cells15,30,34. GAG interaction assessed by Biacore showed that 
NO2-CCL2 is unable to bind both heparin and heparan sulphate. CCL2 binding was achieved but no kinetic mod-
els could be fitted to the data. This is most probably due to complexities of CCL2-GAG interactions. CCL2 can be 
present as a monomer, dimer and large oligomers and both heparan sulphate and heparin, being polymeric and 
heterogeneous in sequence, can display several binding sites with distinct affinities. This suggests that although 
NO2-CCL2 binds to CCR2b, albeit with reduced affinity its inability to support trans-endothelial migration is 
most likely due to reduction in GAG binding.
The potential mechanism by which nitration reduces the interaction with GAGs could be by disruption of 
dimerization. Previous studies have shown that dimerisation of CCL2 is crucial for GAG binding and P8A and 
Figure 5. Surface plasmon resonance assessing the effect of nitration on CCL2- heparan sulphate 
interaction. Chemokines at a range of concentrations (66–500 nM) were injected over sensor chip-immobilised 
A) heparan sulphate or B) heparin, WT-CCL2 left and NO2-CCL2 right, for 5 min, after which running buffer 
was injected, and the response in resonance units (RU) was recorded as a function of time. Biacore sensograms 
are representative of two experiments.
Figure 6. Functional effect of CCL2 nitration on cell recruitment in vivo using a murine air pouch model 
of chemotaxis. Total cell migration into air pouches 18 hr after intrapouch administration of 10 μ g WT-CCL2, 
NO2-CCL2 or PBS only control was determined. Cells were counted by haemocytometer. Statistical analysis by 
ANOVA with Bonferroni post-test. Each symbol represents an animal.
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Y13A mutants are obligate monomers35,36. Supplementary Figure 3 highlights the position of Tyr13 along dimer 
interface. If nitration of Tyr13 affects the ability of CCL2 to dimerise either by altering hydrogen bonding or 
conformation of the protein then GAG binding could be affected. However, the loss in GAG binding in the Y13A 
mutant was not as profound as in NO2-CCL2. Dimerisation is therefore unlikely to be the sole explanation for 
decreased function. Another explanation for the substantial loss of GAG interaction could potentially be due to 
unfolding of the protein. However, our receptor binding data and the ability of NO2-CCL2 to support diffusion 
gradient chemotaxis (albeit at reduced rate) suggests that the N-terminal region is structurally intact.
As expected, the series of in vivo experiments showed that injection of WT-CCL2 resulted in recruitment 
of leukocytes into murine air pouches. In contrast, injection of NO2-CCL2 produced no significant influx of 
inflammatory leukocytes. The in vivo data is consistent with the transendothelial chemotaxis assays performed in 
vitro, and suggests that the presentation of GAG-bound chemokine is also required to promote the physiological 
leukocyte migration which leads to inflammation.
A further series of experiments was performed to assess the potential of systemic administration of NO2-CCL2 
to modulate the infiltration by mononuclear leukocytes of WT-CCL2 filled air pouches. Importantly, it was found 
that i.v. administration of WT-CCL2 enhanced infiltration of the air pouches, while administration of NO2-CCL2 
effectively prevented the recruitment of mononuclear leukocytes to air pouches. As seen with other non-GAG 
binding chemokines it is possible that the NO2-CCL2 exists in circulation for a longer period of time compared 
with WT-chemokines which are sequestered by anionic GAGs15. Chronic exposure to NO2-CCL2 in the circu-
lation can lead to reduced leukocyte-surface expression of CCR2, reduced chemotactic response of these cells to 
WT-CCL2, and inhibit normal chemokine-mediated induction of adhesion.
The majority of studies assessing the involvement of chemokine in disease assume the chemokine to be fully 
functional. Not only is this over simplification, especially in vivo but may be an important confounding factor for 
the failure of chemokine based drug trials. Most of the current detection methods do not differentiate between 
different forms of chemokines. Further, analysis of the role of chemokines in disease is necessary and may explain 
certain paradoxes found between clinical outcome and chemokine levels37.
There is increasing recognition that although targeting infiltrating immune cells can control the inflammatory 
response it does not lead to permanent resolution of inflammation. Resolution therapies can act differently by 
being for example receptor agonists which switch on protective mechanisms that lead to return of homeostasis. 
At present no drugs have been specifically designed to activate pro-resolving pathways. However, there are drugs 
which mediate their affect partly by inducing the synthesis of endogenous anti-inflammatory mediators. For 
example methotrexate and FK506 are thought to increase the synthesis of adenosine which acts through A2A 
adenosine receptor to control leukocyte trafficking38.
The generation of non-GAG binding NO2-chemokines during episodes of inflammation-associated oxidative 
stress suggests a mechanism to limit further leukocyte recruitment leading to the resolution of inflammation. 
Further development of this understanding might suggest improved methods for therapeutic anti-inflammatory 
therapy following organ transplantation.
Materials and Methods
All tissue culture work was carried out in accordance with the ‘Safe Working with Biological Hazards’, ‘Safe 
Working with Chemicals in the Laboratory’ and ‘A Basic Guide for Radiation Workers’ publications and the 
University of Newcastle Upon Tyne Safety Policy.
Human tissue access was approved by Research Ethics Committee approval, Ref. -11/NE/0352. Informed con-
sent was obtained from all subjects. All animal procedures were approved by the Home Office UK and conducted 
in accordance with the requirements of the UK Animals (Scientific Procedures) Act 1986 (Home Office License 
PPL60/3772).
Figure 7. NO2-CCL2 can antagonise the effects of CCL2 in vivo. Total cell migration into murine air 
pouches was determined 18 hr after intrapouch administration of 10 μ g CCL2 or PBS only control and I.V. 
administration of 20 μ g CCL2, NO2-CCL2 or PBS only control. Cells were counted by haemocytometer. 
Statistical analysis by ANOVA with Bonferroni post-test. Each symbol represents an animal.
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Chemokine nitration. Chemokine nitration was achieved by adding peroxynitrite (Cayman Chemical) at 
a final concentration of 1 mM, to 1 μ M CCL2 in dH2O and incubating at 37 °C for up to 10 min. Chemokine was 
freshly nitrated for each experiment and all chemokines were purchased from Almac, UK.
The exact residues modified by peroxynitrite were identified by mass spectrometry. Tryptic digestion was 
performed prior to LC-MS/MS and the data were analysed using Mascot (Matrix Science) as described earlier39.
Immunofluorescence. Formalin-fixed paraffin-embedded (FFPE) tissue sections from patient biopsies 
diagnosed with ATN, 1 week post-kidney transplant were dewaxed (Research Ethics Committee approval, Ref. 
-11/NE/0352). Antigen retrieval was carried out using citrate buffer (pH6) for 2 mins. Sections were blocked for 
30 mins with 20% normal goat serum. They were stained sequentially, with primary antibody overnight at 4 °C 
and secondary for 2 hours at room temperature. Anti-nitrotyrosine polyclonal (1/500, Millipore) was detected 
using a FITC conjugated secondary antibody (1/300, Sigma), and anti-CCL2 polyclonal (1/500, Abcam) was 
detected using a Dylight-550 conjugated secondary antibody (1/100, Immunoreagents). Slides were then incu-
bated in 0.1% Sudan Black B in 70% Ethanol for 20 minutes at room temperature, washed in PBS, and mounted 
using Vectashield mounting medium (Vector Labs). Co-localization analysis was performed, and cytofluoro-
grams generated, using Volocity software (Perkin Elmer).
Cell isolation and culture. Peripheral blood mononuclear cells (PBMC) were isolated from whole blood 
taken from healthy volunteers. Ethical approval to obtain blood from healthy volunteers was granted by the 
Research Ethics Committee (12/NE/0121). PBMC were isolated from heparinised blood using Lympholyte-H 
(Cedarlane Laboratories) as per manufacturer’s instructions. Cells were serum starved for 1 hr prior to use in 
assays.
HEK-CCR2b cells40 were cultured in complete DMEM with 800 μ g/ml G418 (Calbiochem). The THP-1 
monocytic cell line (ATCC TIB-202) was cultured in complete RPMI-1640.
Chemotaxis assays. Diffusion gradient chemotaxis assays were performed in a transwell system in 24 well 
companion plates (BD Falcon) as described previously34. For monocyte chemotaxis, 5 × 105 cells were placed in 
the upper well of a 3 μ m cell culture insert above 0–50 nM CCL2 or NO2-CCL2 in 0.1% BSA/RPMI. The assay was 
incubated at 37 °C for 90 min. Migrated monocytes adhered to the underside of the filter were fixed in methanol, 
stained with haematoxylin, and 5 high power fields (x400) were counted per filter.
For HEK-CCR2b chemotaxis, fibronectin coated 8 μ m inserts were used. The undersides of filters were coated 
with 80 μ l 2.5 μ g/ml fibronectin (Sigma) for 30 min. 2 × 105 cells were placed in the upper well and allowed to 
migrate towards a range of chemokine concentrations for 6 hr at 37 °C.
In vitro, transendothelial chemotaxis assays were performed as above (monocytes) except 72 hr prior to the 
assay, 5 × 104 EA.hy-926 cells were cultured in 0.5 ml complete RPMI in cell culture inserts29. All assays were 
performed in triplicate.
Chemokine receptor binding assays. 2 × 105 HEK-CCR2b per tube were resuspended in 30 μ l binding 
buffer (1 mM CaCl2, 5 mM MgCl2, 50 mM HEPES, 0.5% BSA, pH7.2). 100 μ l CCL2 or NO2-CCL2 in binding 
buffer was then added at a final concentration of 0.1–650 nM, along with a tracer amount of [125I]-CCL2 (Perkin 
Elmer) in 20 μ l binding buffer. Tubes were incubated on ice with agitation for 2 hr. Cells were then washed twice 
using wash buffer (binding buffer with 0.5 M NaCl) before resuspending in 1 ml dH2O. A negative control with 
unlabelled chemokine was also performed. Counts per minute (CPM) were measured using a gamma coun-
ter (Perkin Elmer) and background radiation readings subtracted from results. Experiments were performed 
three times in triplicate and IC50 values calculated using ‘one site competition analysis’ using Prism 5.0 software 
(GraphPad, San Diego, CA, USA).
Heparan sulphate binding assays. Surface plasmon resonance was performed using a BIAcore 3000 
as described previously41,42. Briefly, heparin or heparan sulphate was biotinylated at the reducing end and 
immobilised to a CM4 sensor chip (GE Healthcare). The chip surface was activated with 50 μ l 0.2 M 1-ethyl-3
-(3-dimethylaminopropyl)-carbodiimide and 50 μ l 0.05M N-hydroxysuccinimide before injection of 50 μ l of 
streptavidin (0.2 mg/ml in 10 mM acetate buffer, pH 4.2). Remaining activated groups were blocked with a 5 min 
injection of 1 M ethanolamine HCl, pH 8.5. Biotinylated heparan sulphate was immobilised by injecting 5 μ l of 
50 μ g/ml HS in Hanks’ Balanced Salts with 0.3 M NaCl at a flow rate of 5 μ l/min and injections repeated until a 
resonance unit (RU) increase of 200 reached after which the surface was then washed with 2 M NaCl. For binding 
assays, a range of chemokine concentrations (0–500 nM) were passed across the chip at 25 μ l/min for 5 mins fol-
lowed by a 500 sec dissociation phase and a 2 min injection of 1 M NaCl to regenerate the sensor surface. RU from 
a flow cell coated with streptavidin only was subtracted from the results from GAG coated flow cells and analysis 
was performed using BIAevaluation.
Cell recruitment to murine air pouches. Eight-week-old female BALB/c mice (Charles River, UK) 
were used for generation of air pouches as described previously25. Studies were performed in accordance with 
the United Kingdom Animals (Scientific Procedures) Act 1986 (Home Office License PPL60/3772). Briefly, air 
pouches were generated by injecting 3 ml of sterile air subcutaneously into the back of each animal, followed by 
1 ml of air on day 2, 4, and 5, creating stable fluid-filled pouches. On day 6, each pouch was injected with 1 ml PBS 
containing either 10 μ g CCL2 or NO2-CCL2. Age and sex-matched control mice were injected with PBS alone.
After 18 hr, recruited cells were recovered by gently lavaging the pouch twice with 0.75 ml of PBS. The exudates 
were centrifuged at 500× g for 5 min and the cells resuspended in PBS for analysis by haemocytometer and flow-
cytometry. An example of the gating used during flow cytometric analysis is shown in Supplementary Figure 4. 
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In further experiments air pouches were generated as above and PBS ± 20 μ g CCL2 was injected into the tail vein 
immediately before injection of chemokine into the pouch.
Statistical analyses. All results are expressed as means ± SEM of replicate samples. The significance of 
changes was assessed by the application of an ANOVA with Bonferroni post-test or two-tailed Student’s t-test. All 
data were analysed using Prism 5.0 software.
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